Issue Date: February 1, 2016 | Web Date: January 29, 2016
Return On Pharma R&D Spending Hits New Low In 2015
Every silver lining has its cloud. Although FDA’s approval of 45 new drugs in 2015 is an almost two-decade high, the returns that large pharmaceutical companies generated from their R&D investments hit a new low. In 2015, the average rate of return fell to 4.2% from 10.1% in 2010, according to the Deloitte Centre for Health Solutions.
Deloitte, a consulting firm, factored in development costs and . . .
You Do Not Have Access to C&EN Protected Content.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society